Insmed rises as quarterly revenue beats estimates
Shares of Insmed INSM.O up 4.6% at $158.34 after reporting better-than-expected quarterly revenue
Stock on track for fourth straight session of gains and biggest daily percentage jump since December 19
INSM's quarterly revenue more than doubles to $263.84 million, surpassing analysts' expectations of $171.40 million - data compiled by LSEG
Posts adj. loss per share of $1.54, greater than estimates of $1.29
Anticipates up to $1 billion in full-year revenue from its non-cystic fibrosis medication BRINSUPRI, which received approvals from the European Commission in November and the U.S. FDA in August last year
Average rating of 20 analysts covering INSM is "buy"; median PT is $212
INSM down ~9% YTD vs. S&P 500 healthcare index's .SPXHC 1% gain
Related Articles
New Fed Chair Warsh Takes Office: Major Shift in Monetary Policy? US Dollar Short-Term Rebound, 2026 Investment Strategy Analysis
TradingKey - At the start of 2026, global financial markets witnessed a major leadership change as U.S. President Trump officially nominated Kevin Warsh as the next Federal Reserve Chair. Pending Senate confirmation, he will succeed Jerome Powell this May to lead the world’s most influential central bank.
Should You Buy Berkshire Hathaway Post-Warren Buffett? What's Warren Buffett's Advice for 2026 Investment?
Berkshire built up a hoard of cash through 2025, accumulating nearly $400 billion—more than it had ever held before. That was by design. Berkshire, instead of joining the artificial intelligence rally that led the headlines, put the cash into short-term U.S. Treasuries with about 3.6% yields.
Digital Asset Rotation: Navigating Market Volatility With the Best Cheap Cryptos for 2026
Navigate the 2026 crypto rotation: Analyze the best cheap cryptos like Solana, Chainlink, and XRP amid Bitcoin’s volatility. Discover top picks for utility and long-term gains.
